Moreover, the combined administration of lenti-YAP and Ad-SOX9 significantly increased the oncogenic properties of HCC cells comparing to the treatment of either lenti-YAP or Ad-SOX9 (Fig. 1g; supplementary Fig. 1f, g). The gene discussed is SOX9; the disease is hepatocellular carcinoma.